OPEN ACCESS Freely available online

Molecular Pathology and Biochemistry

Commentary

Molecular Diagnostics in Infectious Diseases: Advances and Challenges

Peter Novak*

Department of Molecular Pathology, Charles University, Prague, Czech Republic.

ABOVE THE STUDY

Molecular diagnostics has revolutionized the field of infectious diseases, fundamentally changing how pathogens are detected, characterized, and monitored. In my view, it represents one of the most impactful transitions in modern medicine, shifting diagnosis from culture-based, time-consuming methods to rapid, highly sensitive molecular techniques. This transformation has not only improved patient outcomes but also enhanced our ability to respond to outbreaks and emerging infectious threats with unprecedented speed.

At the core of molecular diagnostics is the detection of pathogen-specific nucleic acids using techniques such as Polymerase Chain Reaction (PCR), real-time Quantitative PCR (qPCR), and Next-Generation Sequencing (NGS). These technologies allow for the identification of infectious agents even at very low concentrations, often before clinical symptoms fully develop. This early detection capability is particularly important in diseases where rapid progression can lead to severe complications or death, such as sepsis, viral hemorrhagic fevers, and respiratory infections.

One of the most significant advances in this field is multiplex PCR, which enables simultaneous detection of multiple pathogens in a single test. This is especially useful in respiratory and gastrointestinal infections, where clinical symptoms overlap across different pathogens. In my opinion, multiplex platforms have greatly improved diagnostic efficiency, reducing the need for sequential testing and allowing for faster clinical decision-making.

Next-generation sequencing has further expanded the scope of molecular diagnostics. Unlike targeted PCR-based methods, NGS provides comprehensive information about all genetic material in a sample, enabling pathogen discovery, strain typing, and antimicrobial resistance profiling. This has been particularly valuable in outbreak investigations, where identifying novel or mutated pathogens is critical. During recent global pandemics, sequencing technologies played a central role in tracking viral evolution and guiding public health responses.

Despite these advancements, the clinical implementation of molecular diagnostics faces several challenges. One major issue is the distinction between colonization and active infection. The high sensitivity of molecular methods means that they may detect non-viable organisms or commensal flora, potentially leading to overdiagnosis. This raises important questions about how to interpret positive results in the absence of clear clinical correlation.

Another challenge is the detection of antimicrobial resistance. While molecular assays can identify known resistance genes, they may miss novel or complex resistance mechanisms that arise through mutations or gene regulation changes. In my view, this limitation highlights the need for continuous updating of diagnostic panels and integration with phenotypic susceptibility testing.

Cost and accessibility also remain significant barriers, particularly in low-resource settings. Advanced molecular platforms require specialized equipment, trained personnel, and stable laboratory infrastructure. As a result, many regions with the highest burden of infectious diseases have limited access to these technologies. This disparity underscores the importance of developing affordable, portable, and user-friendly diagnostic tools, such as point-of-care molecular assays.

The integration of molecular diagnostics with digital health technologies is another emerging trend. Automated platforms, cloud-based data sharing, and artificial intelligence are increasingly being used to interpret complex diagnostic data and support clinical decision-making. In my opinion, these innovations have the potential to reduce human error, improve turnaround times, and enable real-time surveillance of infectious diseases at a population level.

However, the growing reliance on molecular data also raises concerns about data interpretation and clinical context. A positive molecular result does not always equate to clinically significant infection, and overreliance on laboratory findings without considering patient symptoms can lead to mismanagement. Therefore, molecular diagnostics should complement, not replace, clinical judgment.

Correspondence to Peter Novak, Department of Molecular Pathology, Charles University, Prague, Czech Republic. E-mail: peter.novak@cuni.cz

Received: 15-May-2025, Manuscript No. JMPB-25-41752; **Editor assigned:** 19-May-2025, PreQC No. JMPB-25-41752 (PQ); **Reviewed:** 02-Jun-2025, QC No. JMPB-25-41752; **Revised:** 09-Jun-2025, Manuscript No. JMPB-25-41752 (R); **Published:** 16-Jun-2025. DOI: 10.35248/jmpb.25.6.214.

Citation: Novak P (2025). Molecular Diagnostics in Infectious Diseases: Advances and Challenges. J Mol Pathol Biochem.6:214.

Ethical considerations are also important, particularly in the context of genomic sequencing of pathogens. Issues related to data privacy, pathogen sharing, and global equity in access to diagnostic information must be carefully addressed to ensure fair and responsible use of these technologies.

In conclusion, molecular diagnostics has transformed infectious disease management by enabling rapid, sensitive, and precise pathogen detection. While significant advances such as multiplex PCR and next-generation sequencing have greatly enhanced diagnostic capabilities, challenges related to interpretation, cost, resistance detection, and accessibility remain. In my view, the future of infectious disease diagnostics lies in integrating molecular technologies with clinical insight, digital platforms, and global health strategies to create a more responsive and equitable diagnostic ecosystem.